@article{Phiri2021-oy,

title = {The duration of protection from azithromycin against malaria,  acute respiratory, gastrointestinal, and skin infections when  given alongside seasonal malaria chemoprevention: Secondary  analyses of data from a clinical trial in hound\'{e}, Burkina  Faso, and bougouni, Mali},

author = {Mphatso Dennis Phiri and Matthew Cairns and Issaka Zongo and Frederic Nikiema and Modibo Diarra and Rakiswend\'{e} Serge Yerbanga and Amadou Barry and Amadou Tapily and Samba Coumare and Ismaila Thera and Irene Kuepfer and Paul Milligan and Halidou Tinto and Alassane Dicko and Jean Bosco Ou\'{e}draogo and Brian Greenwood and Daniel Chandramohan and Issaka Sagara},

doi = {10.1093/cid/ciaa1905},

issn = {1537-6591 1058-4838},

year  = {2021},

date = {2021-10-01},

urldate = {2021-10-01},

journal = {Clin. Infect. Dis.},

volume = {73},

number = {7},

pages = {e2379--e2386},

publisher = {Oxford University Press (OUP)},

abstract = {BACKGROUND: Mass drug administration (MDA) with azithromycin 

 (AZ) is being considered as a strategy to promote child survival 

 in sub-Saharan Africa, but the mechanism by which AZ reduces 

 mortality is unclear. To better understand the nature and extent 

 of protection provided by AZ, we explored the profile of 

 protection by time since administration, using data from a 

 household-randomized, placebo-controlled trial in Burkina Faso 

 and Mali. METHODS: Between 2014 and 2016, 30 977 children aged 

 3-59 months received seasonal malaria chemoprevention (SMC) with 

 sulfadoxine-pyrimethamine plus amodiaquine and either AZ or 

 placebo monthly, on 4 occasions each year. Poisson regression 

 with gamma-distributed random effects, accounting for the 

 household randomization and within-individual clustering of 

 illness episodes, was used to compare incidence of prespecified 

 outcomes between SMC+AZ versus SMC+placebo groups in fixed time 

 strata post-treatment. The likelihood ratio test was used to 

 assess evidence for a time-treatment group interaction. RESULTS: 

 Relative to SMC+placebo, there was no evidence of protection 

 from SMC+AZ against hospital admissions and deaths. Additional 

 protection from SMC+AZ against malaria was confined to the first 

 2 weeks post-administration (protective efficacy (PE): 24.2% 

 [95% CI: 17.8%, 30.1%]). Gastroenteritis and pneumonia were 

 reduced by 29.9% [21.7; 37.3%], and 34.3% [14.9; 49.3%], 

 respectively, in the first 2 weeks postadministration. 

 Protection against nonmalaria fevers with a skin condition 

 persisted up to 28 days: PE: 46.3% [35.1; 55.6%]. CONCLUSIONS: 

 The benefits of AZ-MDA are broad-ranging but short-lived. To 

 maximize impact, timing of AZ-MDA must address the challenge of 

 targeting asynchronous morbidity and mortality peaks from 

 different causes.},

note = {© The Author(s) 2021. Published by Oxford University Press for the Infectious Diseases Society of America.

PMID: 33417683 

PMCID: PMC8492219},

keywords = {Antimalarials/therapeutic use, Azithromycin, Azithromycin/therapeutic use, Burkina Faso/epidemiology, Chemoprevention, Child, child mortality, Drug Combinations, duration of protection, Humans, Infant, Malaria/drug therapy/epidemiology/prevention \& control, Mali/epidemiology, Preschool, Sahel, seasonal malaria chemoprevention, Seasons},

pubstate = {published},

tppubtype = {article}

}

@article{Yameogo2021-bb,

title = {Effect of seasonal malaria chemoprevention plus azithromycin on  Plasmodium falciparum transmission: gametocyte infectivity and  mosquito fitness},

author = {Koudraogo Bienvenue Yam\'{e}ogo and Rakiswend\'{e} Serge Yerbanga and Seydou Bienvenu Ouattara and Franck A Yao and Thierry Lef`evre and Issaka Zongo and Frederic Niki`ema and Yves Daniel Compaor\'{e} and Halidou Tinto and Daniel Chandramohan and Brian Greenwood and Adrien M G Belem and Anna Cohuet and Jean Bosco Ou\'{e}draogo},

doi = {10.1186/s12936-021-03855-3},

issn = {1475-2875},

year  = {2021},

date = {2021-07-27},

urldate = {2021-07-27},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {326},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Seasonal malaria chemoprevention (SMC) consists of administration of sulfadoxine-pyrimethamine (SP) + amodiaquine (AQ) at monthly intervals to children  during the malaria transmission period. Whether the addition of azithromycin (AZ) to  SMC could potentiate the benefit of the intervention was tested through a  double-blind, randomized, placebo-controlled trial. The effect of SMC and the  addition of AZ, on malaria transmission and on the life history traits of Anopheles  gambiae mosquitoes have been investigated. METHODS: The study included 438 children  randomly selected from among participants in the SMC + AZ trial and 198 children  from the same area who did not receive chemoprevention. For each participant in the  SMC + AZ trial, blood was collected 14 to 21 days post treatment, examined for the  presence of malaria sexual and asexual stages and provided as a blood meal to An.  gambiae females using a direct membrane-feeding assay. RESULTS: The SMC treatment,  with or without AZ, significantly reduced the prevalence of asexual Plasmodium  falciparum (LRT X(2)(2) = 69, P \< 0.0001) and the gametocyte prevalence (LRT  X(2)(2) = 54, P \< 0.0001). In addition, the proportion of infectious feeds (LRT  X(2)(2) = 61, P \< 0.0001) and the prevalence of oocysts among exposed mosquitoes  (LRT X(2)(2) = 22.8, P \< 0.001) was reduced when mosquitoes were fed on blood from  treated children compared to untreated controls. The addition of AZ to SPAQ was  associated with an increased proportion of infectious feeds (LRT X(2)(1) = 5.2,  P = 0.02), suggesting a significant effect of AZ on gametocyte infectivity. There  was a slight negative effect of SPAQ and SPAQ + AZ on mosquito survival compared to  mosquitoes fed with blood from control children (LRTX(2)(2) = 330, P \< 0.0001).  CONCLUSION: This study demonstrates that SMC may contribute to a reduction in human  to mosquito transmission of P. falciparum, and the reduced mosquito longevity  observed for females fed on treated blood may increase the benefit of this  intervention in control of malaria. The addition of AZ to SPAQ in SMC appeared to  enhance the infectivity of gametocytes providing further evidence that this  combination is not an appropriate intervention.},

note = {© 2021. The Author(s).

PMID: 34315475 

PMCID: PMC8314489},

keywords = {Amodiaquine/administration \& dosage, Animals, Antimalarials/administration \& dosage, Chemoprevention, Child, Culicidae/physiology, Drug Combinations, Falciparum/prevention \& control/transmission, Gametocytes, Genetic Fitness, Humans, Malaria, Plasmodium falciparum/physiology, Preschool, Pyrimethamine/administration \& dosage, seasonal malaria chemoprevention, Seasons, Sulfadoxine/administration \& dosage, Transmission},

pubstate = {published},

tppubtype = {article}

}

@article{De_Wit2021-yi,

title = {Nutritional status in young children prior to the malaria  transmission season in Burkina Faso and Mali, and its impact on  the incidence of clinical malaria},

author = {Mariken Wit and Matthew Cairns and Yves Daniel Compaor\'{e} and Issaka Sagara and Irene Kuepfer and Issaka Zongo and Amadou Barry and Modibo Diarra and Amadou Tapily and Samba Coumare and Ismaila Thera and Frederic Nikiema and R Serge Yerbanga and Rosemonde M Guissou and Halidou Tinto and Alassane Dicko and Daniel Chandramohan and Brian Greenwood and Jean Bosco Ouedraogo},

doi = {10.1186/s12936-021-03802-2},

issn = {1475-2875},

year  = {2021},

date = {2021-06-22},

urldate = {2021-06-22},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {274},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Malaria and malnutrition remain major problems in 

 Sahel countries, especially in young children. The direct effect 

 of malnutrition on malaria remains poorly understood, and may 

 have important implications for malaria control. In this study, 

 nutritional status and the association between malnutrition and 

 subsequent incidence of symptomatic malaria were examined in 

 children in Burkina Faso and Mali who received either 

 azithromycin or placebo, alongside seasonal malaria 

 chemoprevention. METHODS: Mid-upper arm circumference (MUAC) was 

 measured in all 20,185 children who attended a screening visit 

 prior to the malaria transmission season in 2015. Prior to the 

 2016 malaria season, weight, height and MUAC were measured among 

 4149 randomly selected children. Height-for-age, weight-for-age, 

 weight-for-height, and MUAC-for-age were calculated as 

 indicators of nutritional status. Malaria incidence was measured 

 during the following rainy seasons. Multivariable random effects 

 Poisson models were created for each nutritional indicator to 

 study the effect of malnutrition on clinical malaria incidence 

 for each country. RESULTS: In both 2015 and 2016, nutritional 

 status prior to the malaria season was poor. The most prevalent 

 form of malnutrition in Burkina Faso was being underweight 

 (30.5%; 95% CI 28.6-32.6), whereas in Mali stunting was most 

 prevalent (27.5%; 95% CI 25.6-29.5). In 2016, clinical malaria 

 incidence was 675 per 1000 person-years (95% CI 613-744) in 

 Burkina Faso, and 1245 per 1000 person-years (95% CI 1152-1347) 

 in Mali. There was some evidence that severe stunting was 

 associated with lower incidence of malaria in Mali (RR 0.81; 95% CI 0.64-1.02; p = 0.08), but this association was not seen 

 in Burkina Faso. Being moderately underweight tended to be 

 associated with higher incidence of clinical malaria in Burkina Faso (RR 1.27; 95% CI 0.98-1.64; p = 0.07), while this was the 

 case in Mali for moderate wasting (RR 1.27; 95% CI 0.98-1.64; p = 0.07). However, these associations were not observed in 

 severely affected children, nor consistent between countries. 

 MUAC-for-age was not associated with malaria risk. CONCLUSIONS: 

 Both malnutrition and malaria were common in the study areas, 

 high despite high coverage of seasonal malaria chemoprevention 

 and long-lasting insecticidal nets. However, no strong or 

 consistent evidence was found for an association between any of 

 the nutritional indicators and the subsequent incidence of 

 clinical malaria.},

note = {PMID: 34158054 

PMCID: PMC8220741},

keywords = {Acute malnutrition, Antimalarials/administration \& dosage, Azithromycin/administration \& dosage, Burkina Faso, Burkina Faso/epidemiology, Child, Chronic malnutrition, Female, Humans, Incidence, Infant, Malaria, Malaria/epidemiology/transmission, Male, Nutritional Status, Preschool, seasonal malaria chemoprevention, Seasons},

pubstate = {published},

tppubtype = {article}

}

@article{Post2021-oo,

title = {Altered ex-vivo cytokine responses in children with asymptomatic  Plasmodium falciparum infection in Burkina Faso: An additional  argument to treat asymptomatic malaria?},

author = {Annelies Post and Berenger Kabor\'{e} and Mike Berendsen and Salou Diallo and Ousmane Traore and Rob J W Arts and Mihai G Netea and Leo A B Joosten and Halidou Tinto and Jan Jacobs and Quirijn Mast and Andr\'{e} Ven},

doi = {10.3389/fimmu.2021.614817},

issn = {1664-3224},

year  = {2021},

date = {2021-06-09},

urldate = {2021-06-09},

journal = {Front. Immunol.},

volume = {12},

pages = {614817},

publisher = {Frontiers Media SA},

abstract = {Introduction: Patients with clinical malaria have an increased 

 risk for bacterial bloodstream infections. We hypothesized that 

 asymptomatic malaria parasitemia increases susceptibility for 

 bacterial infections through an effect on the innate immune 

 system. We measured circulating cytokine levels and ex-vivo 

 cytokine production capacity in asymptomatic malaria and 

 compared with controls. Methods: Data were collected from 

 asymptomatic participants \<5 years old with and without positive 

 malaria microscopy, as well as from hospitalized patients \<5 

 years old with clinical malaria, bacteremia, or 

 malaria/bacteremia co-infections in a malaria endemic region of 

 Burkina Faso. Circulating cytokines (TNF-$alpha$, IFN-$gamma$, 

 IL-6, IL-10) were measured using multiplex assays. Whole blood 

 from asymptomatic participants with and without positive malaria 

 microscopy were ex-vivo stimulated with S. aureus, E. coli LPS 

 and Salmonella Typhimurium; cytokine concentrations 

 (TNF-$alpha$, IFN-$gamma$, IL-1$beta$, IL-6, IL-10) were 

 measured on supernatants using ELISA. Results: Included were children with clinical malaria (n=118), bacteremia (n=22), malaria and bacteremia co-infection (n=9), asymptomatic malaria (n=125), and asymptomatic controls (n=237). Children with either 

 clinical or asymptomatic malaria had higher plasma cytokine 

 concentrations than controls. Cytokine concentrations correlated 

 positively with malaria parasite density with the strongest correlation for IL-10 in both asymptomatic (r=0.63) and clinical malaria (r=0.53). Patients with bacteremia had lower circulating 

 IL-10, TNF-$alpha$ and IFN-$gamma$ and higher IL-6 

 concentrations, compared to clinical malaria. Ex-vivo whole 

 blood cytokine production to LPS and S. aureus was significantly 

 lower in asymptomatic malaria compared to controls. Whole blood 

 IFN-$gamma$ and IL-10 production in response to Salmonella was 

 also lower in asymptomatic malaria. Interpretation: In children 

 with asymptomatic malaria, cytokine responses upon ex-vivo 

 bacterial stimulation are downregulated. Further studies are 

 needed to explore if the suggested impaired innate immune 

 response to bacterial pathogens also translates into impaired 

 control of pathogens such as Salmonella spp.},

note = {Copyright © 2021 Post, Kabor\'{e}, Berendsen, Diallo, Traore, Arts, Netea, Joosten, Tinto, Jacobs, de Mast and van der Ven.

PMID: 34177883 

PMCID: PMC8220162},

keywords = {Asymptomatic Diseases, asymptomatic malaria, bacteraemia, Bacteremia, bloodstream infection, Burkina Faso/epidemiology, Cells, Child, Cultured, Cytokines/metabolism, Endemic Diseases, Female, Humans, Infant, iNTS, Lipopolysaccharides/immunology, Malaria/epidemiology/immunology, Male, Parasite Load, Plasmodium falciparum/physiology, Preschool, Salmonella},

pubstate = {published},

tppubtype = {article}

}

@article{Sondo2021-kc,

title = {Assessment of a combined strategy of seasonal malaria  chemoprevention and supplementation with vitamin A, zinc and  Plumpy'Doz™ to prevent malaria and malnutrition in children  under 5 years old in Burkina Faso: a randomized open-label trial  (SMC-NUT)},

author = {Paul Sondo and Marc Christian Tahita and Toussaint Rouamba and Karim Derra and B\'{e}renger Kabor\'{e} and Cheick Sa"id Compaor\'{e} and Florence Ou\'{e}draogo and Eli Rouamba and Hamidou Ilboudo and Estelle A"issa Bambara and Macaire Nana and Edmond Yabr\'{e} Sawadogo and Hermann Sorgho and Athanase Mwinessobaonfou Som\'{e} and Innocent Val\'{e}a and Prabin Dahal and Maminata Traor\'{e}/Coulibaly and Halidou Tinto},

doi = {10.1186/s13063-021-05320-7},

issn = {1745-6215},

year  = {2021},

date = {2021-05-24},

urldate = {2021-05-24},

journal = {Trials},

volume = {22},

number = {1},

pages = {360},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Malaria and malnutrition represent major public 

 health concerns worldwide especially in Sub-Sahara Africa. 

 Despite implementation of seasonal malaria chemoprophylaxis 

 (SMC), an intervention aimed at reducing malaria incidence among 

 children aged 3-59 months, the burden of malaria and associated 

 mortality among children below age 5 years remains high in 

 Burkina Faso. Malnutrition, in particular micronutrient 

 deficiency, appears to be one of the potential factors that can 

 negatively affect the effectiveness of SMC. Treating 

 micronutrient deficiencies is known to reduce the incidence of 

 malaria in highly prevalent malaria zone such as rural settings. 

 Therefore, we hypothesized that a combined strategy of SMC 

 together with a daily oral nutrients supplement will enhance the 

 immune response and decrease the incidence of malaria and 

 malnutrition among children under SMC coverage. METHODS: 

 Children (6-59 months) under SMC coverage receiving vitamin A 

 supplementation will be randomly assigned to one of the three 

 study arms (a) SMC + vitamin A alone, (b) SMC + vitamin A + 

 zinc, or (c) SMC + vitamin A + Plumpy'Doz™ using 1:1:1 

 allocation ratio. After each SMC monthly distribution, children 

 will be visited at home to confirm drug administration and 

 followed-up for 1 year. Anthropometric indicators will be 

 recorded at each visit and blood samples will be collected for 

 microscopy slides, haemoglobin measurement, and spotted onto 

 filter paper for further PCR analyses. The primary outcome 

 measure is the incidence of malaria in each arm. Secondary 

 outcome measures will include mid-upper arm circumference and 

 weight gain from baseline measurements, coverage and compliance 

 to SMC, occurrence of adverse events (AEs), and prevalence of 

 molecular markers of antimalarial resistance comprising Pfcrt, 

 Pfmdr1, Pfdhfr, and Pfdhps. DISCUSSION: This study will 

 demonstrate an integrated strategy of malaria and malnutrition 

 programmes in order to mutualize resources for best impact. By 

 relying on existing strategies, the policy implementation of 

 this joint intervention will be scalable at country and regional 

 levels. TRIAL REGISTRATION: ClinicalTrials.gov NCT04238845 . 

 Registered on 23 January 2020 

 https://clinicaltrials.gov/ct2/show/NCT04238845.},

note = {PMID: 34030705 

PMCID: PMC8142067},

keywords = {Antimalarials/adverse effects, Burkina Faso/epidemiology, Chemoprevention, Child, Child Nutrition Disorders, Dietary Supplements, Humans, Infant, Malaria, Malaria/diagnosis/epidemiology/prevention \& control, Malnutrition, Malnutrition/diagnosis/drug therapy/prevention \& control, Pharmaceutical Preparations, Plumpy’Doz™, Preschool, Randomized controlled trial, Seasonal chemoprevention, Seasons, Vitamin A, Vitamin A/adverse effects, Zinc},

pubstate = {published},

tppubtype = {article}

}

@article{Bognini2021-mk,

title = {Socioeconomic inequalities in curative healthcare-seeking for  children under five before and after the free healthcare  initiative in Sierra Leone: analysis of population-based survey  data},

author = {Joel D Bognini and Sekou Samadoulougou and Mady Ouedraogo and Tiga David Kangoye and Carine Van Malderen and Halidou Tinto and Fati Kirakoya-Samadoulougou},

doi = {10.1186/s12939-021-01474-7},

issn = {1475-9276},

year  = {2021},

date = {2021-05-21},

urldate = {2021-05-21},

journal = {Int. J. Equity Health},

volume = {20},

number = {1},

pages = {124},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: Socioeconomic inequalities between and within countries lead to disparities in the use of health services. These disparities could lead to child  mortality in children under 5 years by depriving them of healthcare. Therefore,  initiatives to remove healthcare fees such as the Free Healthcare Initiative (FHCI)  adopted in Sierra Leone can contribute to reducing these inequities in  healthcare-seeking for children. This study aimed to assess the socioeconomic  inequalities in healthcare-seeking for children under 5 years of age before and  after the implementation of the FHCI. METHODS: Data were included on 1207, 2815,  1633, and 1476 children under 5 years of age with fever from the 2008, 2013, 2016,  and 2019 nationwide surveys, respectively. Concentration curves were drawn for the  period before (2008) and after (2013-2019) the implementation of the FHCI to assess  socioeconomic inequalities in healthcare-seeking. Finally, Erreyger's corrected  concentration indices were calculated to understand the magnitude of these  inequalities. RESULTS: Before the implementation of the FHCI, there were  inequalities in healthcare-seeking for children under five (Erreyger's corrected  concentration index (CI) = 0.168, standard error (SE) = 0.049; p \< 0.001) in favor  of the wealthy households. These inequalities decreased after the implementation of  the FHCI (CI = 0.061, SE = 0.033; p = 0.06 in 2013, CI = 0.039, SE = 0.04; p = 0.32  in 2016, and CI = - 0.0005, SE = 0.362; p = 0.98 in 2019). Furthermore, before the  implementation of the FHCI, a significant pro-rich inequality in the districts of  Kenema (CI = 0.117, SE = 0.168, p = 0.021), Kono (CI = 0.175, SE = 0.078, p = 0.028)  and Western Area Urban (CI = 0.070, SE = 0.032, p = 0.031) has been observed. After  the implementation of the FHCI in 2019, these disparities were reduced, 11 of the 14  districts had a CI around the value of equality, and only in 2 districts the  pro-rich inequality were significant (Western Area Urban (CI = 0.035, SE = 0.016,  p = 0.039) and Western Area Rural (CI = 0.066, SE = 0.030, p = 0.027)). CONCLUSION:  The results of this study demonstrated that socio-economic inequalities in  healthcare-seeking for children have been considerably reduced after the FHCI in  Sierra Leone. To further reduce these inequalities, policy actions can focus on the  increase of availability of health services in the districts where the  healthcare-seeking remained pro-rich.},

note = {PMID: 34020665 

PMCID: PMC8140517},

keywords = {Adolescent, Adult, Child, Children under five, Delivery of Health Care/economics, Female, Health Care Surveys, Healthcare Disparities/economics/statistics \& numerical data, Healthcare utilization, Humans, Infant, Male, Parents/psychology, Patient Acceptance of Health Care/statistics \& numerical data, Preschool, Sierra Leone, Socioeconomic Factors, Young Adult},

pubstate = {published},

tppubtype = {article}

}

@article{Adoke2021-el,

title = {A randomized, double-blind, phase 2b study to investigate the  efficacy, safety, tolerability and pharmacokinetics of a  single-dose regimen of ferroquine with artefenomel in adults and  children with uncomplicated Plasmodium falciparum malaria},

author = {Yeka Adoke and Rella Zoleko-Manego and Serge Ouoba and Alfred B Tiono and Grace Kaguthi and Juv^encio Eduardo Bonzela and Tran Thanh Duong and Alain Nahum and Marielle Bouyou-Akotet and Bernhards Ogutu and Alphonse Ouedraogo and Fiona Macintyre and Andreas Jessel and Bart Laurijssens and Mohammed H Cherkaoui-Rbati and Cathy Cantalloube and Anne Claire Marrast and Rapha"el Bejuit and David White and Timothy N C Wells and Florian Wartha and Didier Leroy and Afizi Kibuuka and Ghyslain Mombo-Ngoma and Daouda Ouattara and Ir`ene Mugenya and Bui Quang Phuc and Francis Bohissou and Denise P Mawili-Mboumba and Fredrick Olewe and Issiaka Soulama and Halidou Tinto and FALCI Study Group},

doi = {10.1186/s12936-021-03749-4},

issn = {1475-2875},

year  = {2021},

date = {2021-05-19},

urldate = {2021-05-19},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {222},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: For uncomplicated Plasmodium falciparum malaria, 

 highly efficacious single-dose treatments are expected to 

 increase compliance and improve treatment outcomes, and thereby 

 may slow the development of resistance. The efficacy and safety 

 of a single-dose combination of artefenomel (800 mg) plus 

 ferroquine (400/600/900/1200 mg doses) for the treatment of 

 uncomplicated P. falciparum malaria were evaluated in Africa 

 (focusing on children $\leq$ 5 years) and Asia. METHODS: The 

 study was a randomized, double-blind, single-dose, multi-arm 

 clinical trial in patients aged \> 6 months to 5 years and 20 

 Asian patients. None of the treatment arms met the target 

 efficacy criterion for PCR-adjusted ACPR at Day 28 (lower limit 

 of 95% confidence interval [CI] \> 90%). PCR-adjusted ACPR at 

 Day 28 [95% CI] in the PP Set ranged from 78.4% [64.7; 88.7%] 

 to 91.7% [81.6; 97.2%] for the 400 mg to 1200 mg ferroquine 

 dose. Efficacy rates were low in Vietnamese patients, ranging 

 from 20 to 40%. A clear relationship was found between drug 

 exposure (artefenomel and ferroquine concentrations at Day 7) 

 and efficacy (primary endpoint), with higher concentrations of 

 both drugs resulting in higher efficacy. Six distinct kelch-13 

 mutations were detected in parasite isolates from 10/272 African 

 patients (with 2 mutations known to be associated with 

 artemisinin resistance) and 18/20 Asian patients (all C580Y 

 mutation). Vomiting within 6 h of initial artefenomel 

 administration was common (24.6%) and associated with lower 

 drug exposures. CONCLUSION: The efficacy of 

 artefenomel/ferroquine combination was suboptimal in African 

 children aged $\leq$ 5 years, the population of interest, and 

 vomiting most likely had a negative impact on efficacy. Trial 

 registration ClinicalTrials.gov, NCT02497612. Registered 14 Jul 

 2015, https://clinicaltrials.gov/ct2/show/NCT02497612?term=NCT02497612\&draw=2\&rank=1.},

note = {PMID: 34011358 

PMCID: PMC8135182},

keywords = {Adamantane/administration \& dosage/analogs \& derivatives, Adolescent, Adult, Aged, Aminoquinolines/administration \& dosage, Benin, Burkina Faso, C580Y, Child, Combination treatment, Double-Blind Method, Drug Combinations, Exposure\textendashresponse, Falciparum/prevention \& control, Female, Ferroquine, Ferrous Compounds/administration \& dosage, Gabon, Humans, Infant, Kelch-13 mutation, Kenya, Malaria, Male, Metallocenes/administration \& dosage, Middle Aged, Mozambique, Parasite clearance, Peroxides/administration \& dosage, Pharmacokinetics/pharmacodynamics, Plasmodium falciparum/drug effects, Preschool, resistance, Uganda, Vietnam, Vomiting, Young Adult},

pubstate = {published},

tppubtype = {article}

}

@article{Gies2021-aw,

title = {Risk of malaria in young children after periconceptional iron  supplementation},

author = {Sabine Gies and Stephen A Roberts and Salou Diallo and Olga M Lompo and Halidou Tinto and Bernard J Brabin},

doi = {10.1111/mcn.13106},

issn = {1740-8709 1740-8695},

year  = {2021},

date = {2021-04-01},

urldate = {2021-04-01},

journal = {Matern. Child Nutr.},

volume = {17},

number = {2},

pages = {e13106},

publisher = {Wiley},

abstract = {This study in Burkina Faso investigated whether offspring of young mothers who had received weekly periconceptional iron supplementation in a randomised controlled  trial were at increased risk of malaria. A child safety survey was undertaken in the  peak month of malaria transmission towards the end of the trial to assess child iron  biomarkers, nutritional status, anaemia and malaria outcomes. Antenatal iron  biomarkers, preterm birth, fetal growth restriction and placental pathology for  malaria and chorioamnionitis were assessed. Data were available for 180 babies  surviving to the time of the survey when their median age was 9 months. Prevalence  of maternal iron deficiency in the last trimester based on low body iron stores was  16%. Prevalence of active placental malaria infection was 24.8%, past infection 59%  and chorioamnionitis 55.6%. Babies of iron supplemented women had lower median  gestational age. Four out of five children ≥ 6 months were iron deficient, and 98%  were anaemic. At 4 months malaria prevalence was 45%. Child iron biomarkers, anaemia  and malaria outcomes did not differ by trial arm. Factors associated with childhood  parasitaemia were third trimester C-reactive protein level (OR 2.1; 95% CI 1.1-3.9),  active placental malaria (OR 5.8; 1.0-32.5, P = 0.042) and child body iron stores  (OR 1.13; 1.04-1.23, P = 0.002). Chorioamnionitis was associated with reduced risk  of child parasitaemia (OR 0.4; 0.1-1.0, P = 0.038). Periconceptional iron  supplementation of young women did not alter body iron stores of their children.  Higher child body iron stores and placental malaria increased risk of childhood  parasitaemia.},

note = {© 2020 The Authors. Maternal \& Child Nutrition published by John Wiley \& Sons Ltd.

PMID: 33236840 

PMCID: PMC7988873},

keywords = {Burkina Faso, child iron, Dietary Supplements/analysis, Female, Folic Acid, Humans, Infant, Malaria, Newborn, periconceptional, placenta, Pregnancy, Premature Birth, Preschool},

pubstate = {published},

tppubtype = {article}

}

@article{Post2021-zl,

title = {Infection Manager System (IMS) as a new hemocytometry-based  bacteremia detection tool: A diagnostic accuracy study in a  malaria-endemic area of Burkina Faso},

author = {Annelies Post and Berenger Kabor\'{e} and Joel Bognini and Salou Diallo and Palpouguini Lompo and Basile Kam and Natacha Herssens and Fred Opzeeland and Christa E Gaast-de Jongh and Jeroen D Langereis and Marien I Jonge and Janette Rahamat-Langendoen and Teun Bousema and Heiman Wertheim and Robert W Sauerwein and Halidou Tinto and Jan Jacobs and Quirijn Mast and Andre J Ven},

doi = {10.1371/journal.pntd.0009187},

issn = {1935-2735 1935-2727},

year  = {2021},

date = {2021-03-01},

urldate = {2021-03-01},

journal = {PLoS Negl. Trop. Dis.},

volume = {15},

number = {3},

pages = {e0009187},

publisher = {Public Library of Science (PLoS)},

abstract = {BACKGROUND: New hemocytometric parameters can be used to 

 differentiate causes of acute febrile illness (AFI). We 

 evaluated a software algorithm-Infection Manager System 

 (IMS)-which uses hemocytometric data generated by Sysmex 

 hematology analyzers, for its accuracy to detect bacteremia in 

 AFI patients with and without malaria in Burkina Faso. Secondary 

 aims included comparing the accuracy of IMS with C-reactive 

 protein (CRP) and procalcitonin (PCT). METHODS: In a prospective 

 observational study, patients of $geq$ three-month-old (range 3 

 months- 90 years) presenting with AFI were enrolled. IMS, blood 

 culture and malaria diagnostics were done upon inclusion and 

 additional diagnostics on clinical indication. CRP, PCT, viral 

 multiplex PCR on nasopharyngeal swabs and bacterial- and malaria 

 PCR were batch-tested retrospectively. Diagnostic classification 

 was done retrospectively using all available data except IMS, 

 CRP and PCT results. FINDINGS: A diagnosis was affirmed in 549/914 (60.1%) patients and included malaria (n = 191) bacteremia (n = 69), viral infections (n = 145), and malaria-bacteremia co-infections (n = 47). The overall 

 sensitivity, specificity, and negative predictive value (NPV) of 

 IMS for detection of bacteremia in patients of $geq$ 5 years 

 were 97.0% (95% CI: 89.8-99.6), 68.2% (95% CI: 55.6-79.1) 

 and 95.7% (95% CI: 85.5-99.5) respectively, compared to 93.9% 

 (95% CI: 85.2-98.3), 39.4% (95% CI: 27.6-52.2), and 86.7% 

 (95% CI: 69.3-96.2) for CRP at $geq$20mg/L. The sensitivity, 

 specificity and NPV of PCT at 0.5 ng/ml were lower at 

 respectively 72.7% (95% CI: 60.4-83.0), 50.0% (95% CI: 

 37.4-62.6) and 64.7% (95% CI: 50.1-77.6) The diagnostic 

 accuracy of IMS was lower among malaria cases and patients \<5 

 years but remained equal to- or higher than the accuracy of CRP. 

 INTERPRETATION: IMS is a new diagnostic tool to differentiate 

 causes of AFI. Its high NPV for bacteremia has the potential to 

 improve antibiotic dispensing practices in healthcare facilities 

 with hematology analyzers. Future studies are needed to evaluate 

 whether IMS, combined with malaria diagnostics, may be used to 

 rationalize antimicrobial prescription in malaria endemic areas. 

 TRIAL REGISTRATION: ClinicalTrials.gov (NCT02669823) 

 https://clinicaltrials.gov/ct2/show/NCT02669823.},

note = {PMID: 33647009 

PMCID: PMC7951874},

keywords = {Adolescent, Automation, Bacteremia/diagnosis, Burkina Faso, C-Reactive Protein/analysis, Child, Coinfection/diagnosis/microbiology/parasitology, Female, Fever of Unknown Origin/diagnosis, Humans, Infant, Laboratory/methods, Malaria/diagnosis, Male, Preschool, Procalcitonin/analysis, Prospective Studies, Sensitivity and Specificity, Software, Virus Diseases/diagnosis},

pubstate = {published},

tppubtype = {article}

}

@article{Lompo2021-sk,

title = {Pathogens associated with acute diarrhea, and comorbidity with  malaria among children under five years old in rural Burkina  Faso},

author = {Palpouguini Lompo and Marc Christian Tahita and Hermann Sorgho and William Kabor\'{e} and Adama Kazienga and Ashmed Cheick Bachirou Nana and Hamtandi Magloire Natama and Isidore Juste Ouindgueta Bonkoungou and Nicolas Barro and Halidou Tinto},

doi = {10.11604/pamj.2021.38.259.15864},

issn = {1937-8688},

year  = {2021},

date = {2021-03-01},

urldate = {2021-03-01},

journal = {Pan Afr. Med. J.},

volume = {38},

pages = {259},

publisher = {Pan African Medical Journal},

abstract = {INTRODUCTION: acute diarrhea in children under five years is a public health problem in developing countries and particularly in malaria-endemic areas where both  diseases co-exist. The present study examined the etiology of childhood diarrhea and  its comorbidity with malaria in a rural area of Burkina Faso. 

METHODS: conventional  culture techniques, direct stools examination, and viruses´ detection by rapid tests  were performed on the fresh stools and microscopy was used to diagnose malaria. Some  risk factors were also assessed. RESULTS: on a total of 191 samples collected, at  least one pathogen was identified in 89 cases (46.6%). The proportions of pathogens  found on the 89 positive stool samples were parasites 51.69% (46 cases), viruses  39.33% (35 cases), and bacteria 14.61% (13 cases), respectively. The relationship  between malaria and infectious diarrhea was significant in viral and parasites  causes (p=0.005 and 0.043 respectively). Fever, vomiting and abdominal pain were the  major symptoms associated with diarrhea, with 71.51%, 31.72% and 23.66%  respectively. The highest viral diarrhea prevalence was reported during the dry  season (OR=5.29, 95% CI: 1.74 - 16.07, p=0.001) while parasite diarrhea was more  encountered during the rainy season (OR=0.41, 95% CI: 0.33 - 0.87, p=0.011).  CONCLUSION: Giardia spp and rotavirus were the leading cause of acute diarrhea in  Nanoro, Burkina Faso with a predominance of rotavirus in children less than 2 years.  Parasite and viral diarrhea were the most pathogens associated with malaria.  However, the high rate of negative stool samples suggests the need to determine  other enteric microorganisms.},

note = {Copyright: Palpouguini Lompo et al.

PMID: 34104307 

PMCID: PMC8164431},

keywords = {Abdominal Pain/epidemiology, Acute Disease, bacteria, Burkina Faso, Burkina Faso/epidemiology, Child, Comorbidity, Diarrhea, Diarrhea/epidemiology/microbiology, Female, Fever/epidemiology, Giardiasis/epidemiology, Humans, Infant, infectious, Malaria, Malaria/epidemiology, Male, parasite, pathogens, Preschool, Prevalence, Risk Factors, rotavirus, Rotavirus Infections/epidemiology, Rural Population, Seasons, Vomiting/epidemiology},

pubstate = {published},

tppubtype = {article}

}

@article{Gansane2021-yh,

title = {Anti-malarial efficacy and resistance monitoring of  artemether-lumefantrine and dihydroartemisinin-piperaquine shows  inadequate efficacy in children in Burkina Faso, 2017-2018},

author = {Adama Gansan\'{e} and Leah F Moriarty and Didier M\'{e}nard and Isidore Yerbanga and Esperance Ouedraogo and Paul Sondo and Rene Kinda and Casimir Tarama and Edwige Soulama and Madou Tapsoba and David Kangoye and Cheick Said Compaore and Ousmane Badolo and Blami Dao and Samuel Tchwenko and Halidou Tinto and Innocent Valea},

doi = {10.1186/s12936-021-03585-6},

issn = {1475-2875},

year  = {2021},

date = {2021-01-19},

urldate = {2021-01-01},

journal = {Malar. J.},

volume = {20},

number = {1},

pages = {48},

publisher = {Springer Science and Business Media LLC},

abstract = {BACKGROUND: The World Health Organization recommends regularly 

 assessing the efficacy of artemisinin-based combination therapy 

 (ACT), which is a critical tool in the fight against malaria. 

 This study evaluated the efficacy of two artemisinin-based 

 combinations recommended to treat uncomplicated Plasmodium 

 falciparum malaria in Burkina Faso in three sites: Niangoloko, 

 Nanoro, and Gourcy. METHODS: This was a two-arm randomized 

 control trial of the efficacy of artemether-lumefantrine (AL) 

 and dihydroartemisinin-piperaquine (DP). Children aged 6-59 

 months old were monitored for 42 days. The primary outcomes of 

 the study were uncorrected and PCR-corrected efficacies to day 

 28 for AL and 42 for DP. Molecular markers of resistance to 

 artemisinin derivatives and partner drugs were also analysed. 

 RESULTS: Of 720 children enrolled, 672 reached study endpoints 

 at day 28, 333 in the AL arm and 339 in the DP arm. 

 PCR-corrected 28-day per protocol efficacy in the AL arm was 

 74% (64-83%) in Nanoro, 76% (66-83%) in Gourcy, and 92% 

 (84-96%) in Niangoloko. The PCR-corrected 42-day per protocol 

 efficacy in the DP arm was 84% (75-89%) in Gourcy, 89% 

 (81-94%) in Nanoro, and 97% (92-99%) in Niangoloko. No Pfk13 

 mutation previously associated with artemisinin-resistance was 

 observed. No statistically significant association was found 

 between treatment outcome and presence of the 86Y mutation in 

 the Pfmdr1 gene. There was also no association observed between 

 treatment outcome and Pfpm2 or Pfmdr1 copy number variation. 

 CONCLUSION: The results of this study indicate evidence of 

 inadequate efficacy of AL at day 28 and DP at day 42 in the same 

 two sites. A change of first-line ACT may be warranted in 

 Burkina Faso. Trial Registry Pan African Clinical Trial Registry 

 Identifier: PACTR201708002499311. Date of registration: 8/3/2017 

 https://pactr.samrc.ac.za/Search.aspx.},

keywords = {Antimalarial, Antimalarials/pharmacology, Artemether, Artemether-lumefantrine, Artemisinins/pharmacology, Burkina Faso, Child, Dihydroartemisinin-piperaquine, Drug Resistance, Efficacy, Falciparum/drug therapy, Female, Lumefantrine Drug Combination/pharmacology, Malaria, Male, Plasmodium falciparum, Preschool, Quinolines/pharmacology},

pubstate = {published},

tppubtype = {article}

}

@article{Skrip2020-fq,

title = {Clinical management and mortality among COVID-19 cases in  sub-Saharan Africa: A retrospective study from Burkina Faso and  simulated case analysis},

author = {Laura Skrip and Karim Derra and Mikaila Kabor\'{e} and Navideh Noori and Adama Gansan\'{e} and Innocent Val\'{e}a and Halidou Tinto and Bicaba W Brice and Mollie Van Gordon and Brittany Hagedorn and Herv\'{e} Hien and Benjamin M Althouse and Edward A Wenger and Andr\'{e} Lin Ou\'{e}draogo},

doi = {10.1016/j.ijid.2020.09.1432},

issn = {1878-3511 1201-9712},

year  = {2020},

date = {2020-12-01},

urldate = {2020-12-01},

journal = {Int. J. Infect. Dis.},

volume = {101},

pages = {194--200},

publisher = {Elsevier BV},

abstract = {BACKGROUND: Absolute numbers of COVID-19 cases and deaths 

 reported to date in the sub-Saharan Africa (SSA) region have 

 been significantly lower than those across the Americas, Asia 

 and Europe. As a result, there has been limited information 

 about the demographic and clinical characteristics of deceased 

 cases in the region, as well as the impacts of different case 

 management strategies. METHODS: Data from deceased cases 

 reported across SSA through 10 May 2020 and from hospitalized 

 cases in Burkina Faso through 15 April 2020 were analyzed. 

 Demographic, epidemiological and clinical information on 

 deceased cases in SSA was derived through a line-list of 

 publicly available information and, for cases in Burkina Faso, 

 from aggregate records at the Centre Hospitalier Universitaire 

 de Tengandogo in Ouagadougou. A synthetic case population was 

 probabilistically derived using distributions of age, sex and 

 underlying conditions from populations of West African countries 

 to assess individual risk factors and treatment effect sizes. 

 Logistic regression analysis was conducted to evaluate the 

 adjusted odds of survival for patients receiving oxygen therapy 

 or convalescent plasma, based on therapeutic effectiveness 

 observed for other respiratory illnesses. RESULTS: Across SSA, 

 deceased cases for which demographic data were available were 

 predominantly male (63/103, 61.2%) and aged \>50 years (59/75, 

 78.7%). In Burkina Faso, specifically, the majority of deceased 

 cases either did not seek care at all or were hospitalized for a 

 single day (59.4%, 19/32). Hypertension and diabetes were often 

 reported as underlying conditions. After adjustment for sex, age 

 and underlying conditions in the synthetic case population, the 

 odds of mortality for cases not receiving oxygen therapy were 

 significantly higher than for those receiving oxygen, such as 

 due to disruptions to standard care (OR 2.07; 95% CI 

 1.56-2.75). Cases receiving convalescent plasma had 50% reduced 

 odds of mortality than those who did not (95% CI 0.24-0.93). 

 CONCLUSIONS: Investment in sustainable production and 

 maintenance of supplies for oxygen therapy, along with messaging 

 around early and appropriate use for healthcare providers, 

 caregivers and patients could reduce COVID-19 deaths in SSA. 

 Further investigation into convalescent plasma is warranted 

 until data on its effectiveness specifically in treating 

 COVID-19 becomes available. The success of supportive or 

 curative clinical interventions will depend on earlier treatment 

 seeking, such that community engagement and risk communication 

 will be critical components of the response.},

note = {Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.

PMID: 32987177 

PMCID: PMC7518969},

keywords = {Adolescent, Adult, Africa South of the Sahara, Aged, Antiviral Agents/administration \& dosage, Asia/epidemiology, Burkina Faso, Burkina Faso/epidemiology, Child, Clinical management of SARS-CoV-2 infection: convalescent plasma, COVID-19/drug therapy/epidemiology/mortality/therapy, Europe/epidemiology, Female, Health systems strengthening, Humans, Immunization, Infant, Male, Mortality, Oxygen therapy, Pandemics, Passive, Preschool, Retrospective Studies, SARS-CoV-2 infection, SARS-CoV-2/drug effects/physiology, sub-Saharan Africa, Young Adult},

pubstate = {published},

tppubtype = {article}

}